Screener
Aquestive Therapeutics, Inc. AQST EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:08 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000030
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Interest income and other income, net | 83 | 713 |
| Net loss before income taxes | (8,057) | (22,930) |
| Net loss | $(8,057) | $(22,930) |
| Comprehensive loss | $(8,057) | $(22,930) |
| Loss per share attributable to common stockholders: | ||
| Basic and diluted (in dollars per share) | $(0.07) | $(0.24) |
| Weighted average common shares outstanding: | ||
| Basic and diluted (in shares) | 122,609,995 | 95,497,056 |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s EPS (diluted)?
- Aquestive Therapeutics, Inc. (AQST) reported EPS (diluted) of -$0.07 in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Aquestive Therapeutics, Inc.'s EPS (diluted) increased by 70.8% year-over-year, from -$0.24 to -$0.07.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s EPS (diluted) has grown at a -19.1% compound annual growth rate (CAGR), from -$1.84 to -$0.79.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Aquestive Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude